Gintemetostat: A Promising Treatment for Refractory Multiple Myeloma
A new drug offers hope for patients with advanced multiple myeloma. But here's where it gets controversial: the drug's early success raises questions about its potential impact on future treatment strategies.
Gintemetostat, a novel MMSET/NSD2 inhibitor, has shown promising results in a phase 1 trial (NCT05651932) for patients with triple-class refractory multiple myeloma, a challenging form of the disease. The study, presented at the 2025 ASH Annual Meeting, revealed that gintemetostat was well-tolerated and exhibited encouraging antitumor activity in this heavily pretreated patient population.
In the trial, 40 patients received gintemetostat, with notable responses: 1 patient achieved a very good partial response, 1 had a partial response, 2 had a minimal response, and 12 maintained stable disease. These results are particularly significant as these patients had limited treatment options due to their refractory disease and high-risk features, such as the t(4;14) genetic abnormality.
Lead author Dr. Saad Usmani, a myeloma specialist, highlighted the importance of these findings: "Gintemetostat showed single-agent activity in heavily pretreated patients, including those with the t(4;14) translocation, across various dose levels."
Safety and Efficacy
The phase 1 study's safety profile revealed that 75% of patients experienced treatment-related adverse events, with 45% experiencing grade 3 or higher events. However, these side effects were manageable, and only 3 patients required dose reductions.
As of June 13, 2025, 12 patients continued treatment, while 28 discontinued, primarily due
